Novartis is planning an expanded trial of NIO752 in People with MAPT-FTD, PSP, and CBS. (AFTD) - Oct 20, 2026 - "The goal of the new Phase 2 study is to determine if adverse events in people with FTD occur as a result of the drug...The trial will also evaluate people with diagnoses of progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS)."
Trial status • Frontotemporal Lobar Degeneration • Progressive Supranuclear Palsy
|